20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
07:00 , May 19, 2016 |  BC Innovations  |  Finance

Found in translation

Mark Zipkin, Staff Writer  With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
07:00 , May 19, 2016 |  BC Innovations  |  Strategy

Mind the gap

A wave of initiatives and funds in the U.K. over the last two years has been flooding the gap between the country's prolific scientific achievements and its comparatively low rate of commercialization. The hope is...
07:00 , May 16, 2016 |  BioCentury  |  Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Financial News

Apollo Therapeutics Fund financial update

AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) and Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) will each contribute L10 million ($14.3 million) over the fund’s six-year life. The pharmas will...
02:14 , Jan 26, 2016 |  BC Extra  |  Financial News

Pharmas, U.K. schools launch L40M Apollo fund

Three pharmas and the tech transfer offices of three U.K. universities launched the L40 million ($57 million) Apollo Therapeutics Fund to support development of early stage projects arising from the universities. Apollo will invest in...